ABQ Times

The University of New Mexico Comprehensive Cancer Center has introduced a new Chimeric Antigen Receptor T-Cell (CAR-T) therapy, which utilizes modified white blood cells to combat various cancers such as lymphomas, myelomas, and leukemias that have been resistant to conventional treatments. Dr. Shashank Cingam, who recently joined the center’s Bone Marrow Transplant and Cellular Therapy Team, has played a pivotal role in launching this program.

Dr. Cingam explained that CAR-T therapy is akin to a bone marrow transplant but differs in its approach. "Instead of stem cells, we collect white blood cells," he said. These collected cells are sent to an external lab where they are modified and multiplied to express receptors capable of detecting and killing cancer cells.

Despite using the patients' own white blood cells, a mild chemotherapy regimen is necessary to weaken their immune systems before reintroducing the modified cells. This step prevents the immune system from rejecting these reinforcements. "Once injected, these CAR-T cells multiply in the body and attack the cancer cells directly," Cingam noted.

The response from CAR-T therapy can be swift but varies in duration. "Anywhere between one and seven days is when it’s in its full-blown effect," he said. However, this immune response comes with potential side effects that require close monitoring.

"These are living drugs," Cingam emphasized. "They are multiplying in your body, releasing inflammatory cytokines." To manage these side effects like high-grade fevers or brain inflammation, patients may receive steroids and other anti-inflammatory therapies.

Currently, New Mexico patients often travel significant distances for CAR-T treatment due to the necessity of staying near medical facilities for extended periods post-procedure. The new program at UNM Cancer Center offers a local option that reduces travel burdens for patients and their families.

The center's Bone Marrow Transplant and Cellular Therapy program now provides four commercial CAR-T therapies targeting several types of lymphoma and multiple myeloma. Clinical trials are also underway to explore further applications of this therapy.

Dr. Matthew Fero, director of the Bone Marrow and Stem Cell Transplant Program at UNM Cancer Center, highlighted CAR-T's effectiveness: "It gives patients another great treatment option."

The UNM Comprehensive Cancer Center serves as New Mexico’s official cancer center and holds National Cancer Institute designation within a 500-mile radius. It offers specialized care across numerous oncology fields through its extensive team of healthcare professionals.

In addition to patient care, the center engages in cutting-edge research funded by $38.2 million in grants and contracts since 2015 while contributing significantly to economic development through patents and biotech startups.

Moreover, it plays a crucial role in education by providing training opportunities for over 500 students across various levels annually.